Exploiting synergy: Immune-based combinations in the treatment of prostate cancer

Mauricio Burotto, Nishith Singh, Christopher R. Heery, James L. Gulley*, Ravi A. Madan

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

13 Citas (Scopus)


Cancer treatment is being revolutionized by the emergence of immunotherapies such as immune check point inhibitors and therapeutic cancer vaccines. Prostate cancer has is amenable to such therapeutic approaches. The improved understanding of the relationship between the immune system and tumors has allowed therapeutic targeting of immune checkpoints and tumor associated antigens to be developed. Furthermore, interventions used in prostate cancer are capable of impacting the immune system. As demonstrated by preclinical data and emerging clinical data, radiation therapy, anti-androgen therapy and chemotherapy can be used with immunotherapies to obtain synergistic results. Current and future clinical trials will further investigate these principals as immunotherapeutics are combined with each other and standard therapies for optimal clinical utility.

Idioma originalInglés
Número de artículo351
PublicaciónFrontiers in Oncology
EstadoPublicada - 2014
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2014 Burotto, Singh_, Heery, Gulley and Madan.


Profundice en los temas de investigación de 'Exploiting synergy: Immune-based combinations in the treatment of prostate cancer'. En conjunto forman una huella única.

Citar esto